A combination comprising 2 to 8 mg of 5-[4-[2-(N-methyl-N- (2-pyridyl)amino)-ethoxy]benzyl]thiazolidine-24-dione (rosiglitazone) or a tautomeric form thereof or a pharmaceutically acceptable salt or solvate thereof; and sub maximal amount of sulphonylurea selected from glibenclamide glipizide gliclazide tolazamide tolbutamide acetohexamide carbutamide chlorpropamide glibornuride gliquidone glisentide glisolamide glisoxepide glyclopyamide and glycylamide. Disclosed is also a medical use of the co...

PROBLEM TO BE SOLVED: To provide a therapeutic agent for type II diabetes containing metformin which is a biguanide hypoglycemic drug and 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-24-dione which is an insulin sensitizer inhibiting instability of the agent caused by interaction. SOLUTION: The pharmaceutical composition contains thiazolidinedione dispersed into a pharmaceutically acceptable first carrier and metformin hydrochloride dispersed into a pharmaceutically acceptabl...

Pharmaceutical composition comprising 2 to 8 mg of 5-[4-[2-(N-2-methyl-N-pyridyl)amino)ethoxy]benzyl]tiazolidin-24- dione (rosiglitazone) or a pharmaceutically acceptable salt thereof and a sub-maximal amount of glimepiride. The composition is intended for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in mammals. The invention also relates to the use of the aforementioned pharmaceutical composition.

In the present invention there is described a pharmaceutical composition containing 2 to 8 mg of 5-[4-[2-(N-methyl-N-(2pyridyl)amino)ethoxy]benzyl]thiazolidine-24-dione that means the compound of the general formula (I) or a pharmaceutically acceptable derivative thereof submaximal amount of composition for support of insulin secretion being selected from the group consisting of glibenclamide glipizide gliclazide and glimepiride and a pharmaceutically acceptable carrier. There is also described ...

A pharmaceutical composition comprising a thiazolidinedione such as Compound (I) metformin hydrochloride and a pharmaceutically acceptable carrier wherein the thiazolidinedione and metformin hydrochloride are each dispersed within its own pharmaceutically acceptable carrier in the pharmaceutical composition and the use of such a composition in medicine.

A pharmaceutical composition comprising a thiazolidinedione such as Compound (I) metformin hydrochloride and a pharmaceutically acceptable carrier wherein the thiazolidinedione and metformin hydrochloride are each dispersed within its own pharmaceutically acceptable carrier in the pharmaceutical composition and the use of such a composition in medicine.

PROBLEM TO BE SOLVED: To provide a production method for potassium clavulanate of pharmaceutically acceptable quality by which crude clavulanic acid is directly precipitated as a potassium salt by forming an intermediate amine salt and the clavulanic acid in a solution is reacted with a potassium ion in the solution. SOLUTION: The free clavulanic acid produced in a fermentation process is extracted into an organic solvent to form a solution of the clavulanic acid in the organic solvent and a po...

Pharmaceutical composition suitable for once daily administration which comprises: (a) 2 mg to 12 mg of 5-[4-[2-(N- methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-24-dione i. e. rosiglitazone optionally in the form of a pharmaceutically acceptable salt or solvate thereof; (b) 100 mg to 3000 mg of metformin or a pharmaceutically acceptable salt thereof; and (c) a pharmaceutically acceptable carrier; wherein the composition is arranged to provide sustained release of rosiglitazone and metfor...